Targeting Parkinson's at Its Genetic Root: A New Era of Precision Trials

SOUTH SAN FRANCISCO, CA – June 17, 2026 – A pivotal development in the fight against Parkinson’s disease is unfolding, signaling a strategic shift from managing symptoms to targeting the disease's underlying genetic drivers. Neuron23 Inc., a clinical-stage biotechnology company, has received a $2.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding is set to accelerate the expansion of its Phase 2 NEULARK clinical trial into Israel, a move that underscores the growing momentum behind precision medicine in neurodegenerative disorders.

The trial is evaluating NEU-411, a novel oral LRRK2 inhibitor, in a patient population genetically selected for having LRRK2-driven Parkinson's disease. This convergence of philanthropic support, international collaboration, and cutting-edge science represents more than just another clinical trial; it marks a significant step toward a future where treatments are tailored to an individual's unique biological makeup, fundamentally changing how we approach this complex condition.

A New Strategy: From Symptom to Source

For decades, Parkinson's treatment has focused on alleviating motor symptoms like tremors and stiffness, primarily by replenishing dopamine levels in the brain. While vital for improving quality of life, these therapies do not halt the underlying progression of the disease. Neuron23's approach with NEU-411 represents a significant departure from this paradigm.

The therapy targets Leucine-rich repeat kinase 2 (LRRK2), a protein whose overactivity is linked to Parkinson's pathology. Mutations in the LRRK2 gene are one of the most common genetic causes of the disease, and inhibiting its hyperactivity is believed to be a promising strategy to slow or stop neurodegeneration. NEU-411 is designed as a potent, selective, and brain-penetrant oral inhibitor that directly addresses this root mechanism.

“We believe identifying and treating patients based on the underlying biology driving their disease has the potential to fundamentally change how Parkinson’s disease is treated,” said Arash Rassoulpour, Ph.D., Chief Operating Officer of Neuron23. The company’s strategy extends beyond the approximately 2% of patients with known LRRK2 gene mutations. Neuron23 has identified specific DNA variations, or SNPs, that are predicted to drive LRRK2 overactivity in up to 30% of people with idiopathic Parkinson's—those without a known family history. This vastly expands the potential patient population that could benefit from LRRK2 inhibition, making the NEULARK trial a critical test case for this broader precision medicine approach.

Global Collaboration Fuels a Targeted Attack

The involvement of The Michael J. Fox Foundation is more than just financial; it's a powerful endorsement of the scientific rationale behind the NEULARK trial. As a leading funder of Parkinson's research, MJFF has long championed the investigation of LRRK2 as a therapeutic target.

“At The Michael J. Fox Foundation, we remain steadfast toward our singular and urgent mission of delivering better treatments and a cure for patients living with Parkinson’s disease,” said Shalini Padmanabhan, PhD, the foundation's senior vice president and head of translational research. “We’re moving toward a future where we can define disease by biology, identify it earlier and build more targeted treatments.”

The grant will facilitate the activation of four clinical trial sites across Israel, a country with a unique strategic importance for this research. Israel's population includes a high concentration of Ashkenazi Jews, a group with a significantly higher prevalence of the LRRK2 G2019S mutation. This allows for more efficient recruitment of the specific patient population needed for the study. Furthermore, Israel boasts a world-class clinical and research community.

“LRRK2 remains one of the most compelling therapeutic targets in Parkinson’s disease because it is supported by decades of genetic and biological research,” noted Prof. Roy Alcalay, M.D., chief of the Movement Disorders Division at Tel Aviv Sourasky Medical Center. He added that the trial's expansion “reflects the strong commitment of the movement disorders community to provide access to clinical trials and prospective future targeted therapies in Israel and worldwide.”

Beyond the Clinic: Digital Health Redefines Trial Monitoring

One of the most innovative aspects of the NEULARK trial is its integration of digital technology to monitor patients. The study incorporates a smartphone app equipped with proprietary software from Roche Information Solutions. This tool allows for the frequent, passive measurement of both motor symptoms like tremor and movement, and non-motor symptoms such as cognition.

This marks a significant evolution from traditional clinical trial methodologies, which rely on infrequent, in-clinic assessments like the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS). While the MDS-UPDRS remains a secondary endpoint, the primary measure of efficacy in the NEULARK trial is the change in a digital biomarker score. This approach provides a continuous, objective stream of data collected in the patient's real-world environment, offering a far more detailed and accurate picture of disease status and treatment response.

For patients, this technology reduces the burden of frequent travel to trial sites. For researchers, it provides a richer dataset that can detect subtle changes and accelerate the evaluation process. This use of digital biomarkers is a prime example of how technology is not just supporting but actively improving the way we develop new medicines, making trials more efficient and patient-centric.

A Crowded Field with a Clearer Target

Neuron23 is not alone in recognizing the potential of LRRK2 inhibition. The field is competitive, with major players like Denali Therapeutics (in partnership with Biogen) and Roche/Genentech also advancing LRRK2 inhibitors through late-stage clinical trials. This intense activity validates the scientific community's conviction that this pathway is a critical target for developing a disease-modifying therapy for Parkinson's.

Within this landscape, Neuron23's strategy of prospectively identifying a broad LRRK2-driven population—including those with specific SNPs—sets it apart. By partnering with Sano Genetics to offer free saliva test kits to identify eligible individuals, the company is streamlining recruitment and ensuring it enrolls the patients most likely to respond to NEU-411. This highly targeted approach, combined with robust financial and philanthropic backing, positions the NEULARK trial as a critical program to watch as the industry moves collectively toward a new, more precise era of treating Parkinson's disease.